Our favorite Carlsbad life sciences firm, Invitrogen, has done some shopping. They recently bought CellzDirect, a company that “focuses on hepatocytes that are widely used to predict a compound’s effect on liver metabolism” for $57 million in cash.
“CellzDirect’s high-value products and services will greatly complement Invitrogen’s market-leading portfolio of complete cell systems, including primary cells, media, matrices and growth factors,” said Greg Lucier, Invitrogen’s chairman and chief executive officer, in a statement. “The purchase of CellzDirect follows our strategy of investing in high growth areas of the market, specifically specialty cell systems.”
We’re don’t even know enough to comment on it, but Lucier makes it sound great.
[Link: Local Tech Wire]
RSS Feed-Posts